triple-hormone-receptor agonist retatrutide for obesity 2023年度回顧】 NEJM Notable Articles of 2023 Day 3: Triple–Hormone-Receptor — A Phase 2 Trial. N Engl J Med 2023; 389:514-526. 製圖：Sardinosis Retatrutide Severe Obesity Trial Shows

Based on Phase 2 studies, the initial dose may begin at 1 mg to 2 mg (0.0750.15 mL) once weekly, with gradual titration every 4 weeks in increments of 2 mg to 4 mg, as tolerated, up to a maximum of 12 mg (0.90 mL) weekly Doses between 4 mg and 12 mg weekly demonstrated meaningful reductions in body weight and glycemic parameters over 16 to 28 weeks

Now, shes unstoppable

Others choose Friday evenings for similar reasons

Clinical trial NCT04050670 examined tirzepatide absorption at different sites and found something interesting

Supporting your bodys natural GLP-1 production isnt about forcing appetite down

Wegovy, on the other hand, is specifically designed for chronic weight management and is a potent GLP-1 receptor agonist